Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Buy

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Sell

C

Aadi Bioscience, Inc. Common Stock (AADI)

Pharmaceutical Preparations

https://www.aadibio.com

Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.

17383 SUNSET AVENUE, SUITE A250
PACIFIC PALISADES, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

08/27/2021

Market Cap

35,568,386

Shares Outstanding

24,530,000

Weighted SO

24,525,860

Total Employees

N/A

Upcoming Earnings

08/14/2024

Similar Tickers

ANEB --.--%

ADAG --.--%

ACRV --.--%

ANAB --.--%

MLYS --.--%

ANTX --.--%

AVTE --.--%

GRCL --.--%

THRX --.--%

Beta

0.3100

Last Div

0.0000

Range

1.21-7.24

Chg

-0.0050

Avg Vol

200909

Mkt Cap

35568386

Exch

NASDAQ

Country

US

Phone

424 473 8055

DCF Diff

2.3110

DCF

-0.1410

Div Yield

0.0000

P/S

1.4934

EV Multiple

0.0640

P/FV

0.4954

Div Yield %

0.0000

P/E

-0.5964

PEG

-0.0143

Payout

0.0000

Current Ratio

4.1994

Quick Ratio

3.9241

Cash Ratio

1.8575

DSO

90.7251

DIO

728.8048

Op Cycle

819.5300

DPO

270.7024

CCC

548.8276

Gross Margin

0.8718

Op Margin

-2.9667

Pretax Margin

-2.7477

Net Margin

-2.7477

Eff Tax Rate

0.0006

ROA

-0.6440

ROE

-0.6667

ROCE

-0.8891

NI/EBT

1.0000

EBT/EBIT

0.9262

EBIT/Rev

-2.9667

Debt Ratio

0.0104

D/E

0.0134

LT Debt/Cap

0.0086

Total Debt/Cap

0.0132

Int Coverage

70659.0000

CF/Debt

-39.0606

Equity Multi

1.2897

Rec Turnover

4.0231

Pay Turnover

1.3483

Inv Turnover

0.5008

FA Turnover

3.4092

Asset Turnover

0.2344

OCF/Share

-1.5271

FCF/Share

-1.6254

Cash/Share

2.9088

OCF/Sales

-1.7319

FCF/OCF

1.0643

CF Coverage

-39.0606

ST Coverage

-110.2888

CapEx Coverage

-15.5477

Div&CapEx Cov

-15.5477

P/BV

0.4954

P/B

0.4954

P/S

1.4934

P/E

-0.5964

P/FCF

-0.8102

P/OCF

-0.9462

P/CF

-0.9462

PEG

-0.0143

P/S

1.4934

EV Multiple

0.0640

P/FV

0.4954

DPS

0.0000

Latest Headlines (EST)

Benzinga Dec 15, 14:16 Cancer Player Aadi Bioscience Downgraded: Analyst Highlights 'Worse Than Expected' Response Rates Benzinga Dec 15, 12:46 Why Quanex Building Products Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Revenue Product Segmentation